

AWARD NUMBER: W81XWH-20-1-0268

TITLE: Integration and Recellularization of Microparticles for the Repair of Tissue Defects

PRINCIPAL INVESTIGATOR: Corey P. Neu

CONTRACTING ORGANIZATION: University of Colorado Boulder

REPORT DATE: MAY 2021

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Development Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

1. REPORT DATE MAY 2021			2. REPORT TYPE Annual		3. DATES COVERED 1MAY2020 - 30APR2021	
4. TITLE AND SUBTITLE Integration and Recellularization of Microparticles for the Repair of Tissue Defects					5a. CONTRACT NUMBER W81XWH-20-1-0268	
					5b. GRANT NUMBER	
					5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Corey Neu E-Mail: cpneu@colorado.edu					5d. PROJECT NUMBER	
					5e. TASK NUMBER	
					5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Colorado Boulder Office of Contracts and Grants 3100 Marine St, Rm 481, 527 UCB Boulder, CO. 80309					8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Development Command Fort Detrick, Maryland 21702-5012					10. SPONSOR/MONITOR'S ACRONYM(S)	
					11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited						
13. SUPPLEMENTARY NOTES						
14. ABSTRACT Our proposal advances the use of reconstituted decellularized and particulated articular cartilage, termed 'cartilage clay', as a new tissue repair technology following trauma. Osteoarthritis is a debilitating disease that afflicts nearly 20% of people in the United States and is extremely common among military personnel. In an effort to understand and improve integrative cartilage repair for the treatment of osteoarthritis, we have pioneered tissue engineering technology that utilizes decellularized cartilage microparticles packed in a hydrogel. We are studying the extent that cartilage clay will 1) encourage a regenerative response in damaged tissue regions, 2) mimic the structural support of native tissue, 3) establish an environment that promotes attachment, migration, and differentiation of infiltrating cells, and 4) provide an inductive ECM and source of growth factors and other anti-catabolic growth factors and cytokines. We will optimize the cartilage clay design and establish preclinical efficacy of a new, easy-to-apply cartilage repair strategy that facilitates efficient host cell response <i>in vivo</i> .						
15. SUBJECT TERMS Arthritis						
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON USAMRMC	
a. REPORT	b. ABSTRACT	c. THIS PAGE			19b. TELEPHONE NUMBER (include area code)	
Unclassified	Unclassified	Unclassified	Unclassified			

TABLE OF CONTENTS

	<u>Page</u>
1. INTRODUCTION	4
2. KEYWORDS	4
3. ACCOMPLISHMENTS	4
4. IMPACT	6
5. CHANGES/PROBLEMS	7
6. PRODUCTS	8
7. PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS	8
8. SPECIAL REPORTING REQUIREMENTS	9
9. APPENDICES	10

INTRODUCTION

Our proposal advances the use of reconstituted decellularized and particulated articular cartilage, termed ‘cartilage clay’, as a new tissue repair technology following trauma. Osteoarthritis is a debilitating disease that afflicts nearly 20% of people in the United States and is extremely common among military personnel. In an effort to understand and improve integrative cartilage repair for the treatment of osteoarthritis, we have pioneered tissue engineering technology that utilizes decellularized cartilage microparticles packed in a hydrogel. We are studying the extent that cartilage clay will 1) encourage a regenerative response in damaged tissue regions, 2) mimic the structural support of native tissue, 3) establish an environment that promotes attachment, migration, and differentiation of infiltrating cells, and 4) provide an inductive ECM and source of growth factors and other anti-catabolic growth factors and cytokines. We will optimize the cartilage clay design and establish preclinical efficacy of a new, easy-to-apply cartilage repair strategy that facilitates efficient host cell response *in vivo*.

KEYWORDS

Osteoarthritis, Arthritis, Osteoarthritis, Degeneration, Integrative Repair, Defect, Hydrogel, Microparticles, Morselize, Decellularization, Recellularization

ACCOMPLISHMENTS

What were the major goals of the project?

The major goals of the project are detailed in our SOW table, below. The application listed specific milestones and target dates for important activities or phases of the project. We also identify the actual completion dates and/or percentage of completion.

Activity	Timeline (Months)	Percentage Complete	Completion Date
Specific Aim 1: Define how microparticle density promotes structural support and graft recellularization, and improves integrative defect repair			
Major Task 1: Create Composite Scaffolds and Define Microparticle Density Limits	1	95	<i>In progress</i>
Subtask 1: Fabricate cartilage clay in cartilage defect models <i>in vitro</i> .	1-12	100	4/1/2021
Subtask 2: Investigate the role of percolation, cell type, and cell concentration.	3-6	95	
Subtask 3: Investigate integration quality: structural and ultrastructural properties, cell responses, chemotaxis and durotaxis	3-9	100	11/1/2020
Subtask 4: Multifactor statistical testing	6-12	100	11/1/2020
<i>Milestone(s) Achieved:</i> Define microparticle density that promotes graft support, evaluate tissue integration, identify cell migration mechanisms.	12	100	4/1/2021
Local IACUC approval for large animal studies	9-12	100	1/1/2021
Specific Aim 2: Evaluate integration and recellularization of cartilage clay against clinical benchmarks in a large animal model <i>in vivo</i>			
Major Task 2: Perform Goat Surgeries (12 animals)	12	25	<i>In progress</i>
Subtask 1: Radiographs at biweekly intervals	24 or earlier	25	
Subtask 2: Serum and synovial fluid collections	24 or earlier		

<i>Milestone(s) Achieved:</i> Animal timecourse complete	24		
Major Task 3: Analysis			
Subtask 1: Morphological MRI to assess tissue quality and structure	24-30		
Subtask 2: Quantify biomarkers from serum and synovial fluid	24-30		
Subtask 3: Structural analysis and mechanical testing	30-36		
Subtask 4: Multifactor statistical testing	30-36		
<i>Milestone(s) Achieved:</i> Determine the extent that cartilage clay protects the cartilage and joint from degeneration.	36		

What was accomplished under these goals?

We accomplished activities related to Specific Aim 1 of our proposal, specifically to define how microparticle density promotes structural support and graft recellularization, and improves integrative defect repair. We recently found that cells in contact with microparticles express chondrogenic markers, suggesting that dense packing in cartilage clay increases chondrogenesis. We also showed that cells rapidly recellularize microparticles, and that close packing of particles improves structural support and mechanical properties. We will therefore study limits of particle packing to best provide an implantable scaffold suitable for *in vivo* transplantation, in addition to mechanisms of recellularization in dense cartilage tissue.

We found that cells embedded in the extracellular matrix of tissues play a critical role in maintaining homeostasis while promoting integration and regeneration following damage or disease. Emerging engineered biomaterials utilize decellularized extracellular matrix as a tissue-specific support structure; however, many dense, structured biomaterials unfortunately demonstrate limited formability, fail to promote cell migration, and result in limited tissue repair. Here, we developed a reinforced composite material of densely packed acellular extracellular matrix microparticles in a hydrogel, termed *tissue clay*, that can be molded and crosslinked to mimic native tissue architecture. We utilized hyaluronic acid-based hydrogels, amorphously packed with acellular articular cartilage tissue particulated to ~125-250 microns in diameter and defined a percolation threshold of 0.57 (v/v) beyond which the compressive modulus exceeded 300kPa. Remarkably, primary chondrocytes recellularized particles within 48 hours, a process driven by chemotaxis, exhibited distributed cellularity in large engineered composites, and expressed genes consistent with native cartilage repair. We additionally demonstrated broad utility of tissue clays through recellularization and persistence of muscle, skin, and cartilage composites in a subcutaneous *in vivo* mouse model. Our findings suggest optimal strategies and material architectures to balance concurrent demands for large-scale mechanical properties while also supporting recellularization and integration of dense musculoskeletal and connective tissues.

Importantly, major findings related to Aim 1 are currently under review in two manuscripts: one at *Advanced Functional Materials*, and a second at *Advanced Healthcare Materials*. We hope that both will be published by the next reporting period.

Additionally, through our clinical partner and subcontractor, Colorado State University, we initiated the major Aim 2 animal study. Initial studies found that cartilage clay exhibits exciting properties *in vitro*, suggesting successful translation *in vivo*. In large animal studies, we predict that cartilage clay restores the functional outcomes in an *in vivo* model of defect repair to levels observed in native tissues, and protects the joint from degeneration following trauma. In February, 2021, we initiated study the influence of full thickness defects and cartilage clay repair on cartilage biomechanics in an established *in vivo* caprine (goat) model with treatment groups: microfracture as a standard of care, and graft repair using cartilage clay established in our laboratory. Through an IACUC- and ACURO-approved protocol, we implanted materials in 12 goats. To date, all animals are healthy and active. We are in the process of analyzing the first radiographic time point (~12 weeks), and we will use this information to determine the ongoing progress of cartilage clay efficacy.

What opportunities for training and professional development has the project provided?

Our research has supported training and professional development of (e.g. graduate) students and a postdoctoral researcher. Training in specialized skills was attained in the fields of tissue engineering, tissue mechanics, data and image processing, and biomechanics of animal and human joints. Training was primarily

achieved through one-on-one meetings and guidance from the mentor (PI), and additionally through selected auditing of courses (e.g. on biomaterials) and participation in experiences like large animal surgeries. Professional development has included presentations and networking at national and international meetings, and through attendance of seminars offered by our department and university. Additionally, extensive professional development was achieved through individual study of specialized topics like protocols and ethics involved with human subjects, and commercialization.

How were the results disseminated to communities of interest?

We have disseminated our work to communities of interest through submissions to journal articles and conferences of national and international meetings.

Journal Articles:

Barthold JE, St. Martin BM, Sridhar SL, Vernerey F, Schneider SE, Wacquez A., Ferguson V, Calve S, Neu CP (2021). Recellularization and Integration of Dense Extracellular Matrix by Percolation of Tissue Microparticles. <https://www.biorxiv.org/content/10.1101/2020.08.10.245589v1>; doi: <https://doi.org/10.1101/2020.08.10.245589>. (*Currently under final review at Advanced Functional Materials*)

Barthold JE, McCreery K, Bellerjeau C, Bryant SJ, Whiting GL, Neu CP (2021). Particulate ECM Bioink Crosslinking and 3D Printing Form Layered and Lubricated Cartilage Tissue Mimics. (*Currently under review at Advanced Healthcare Materials*)

Conferences:

Barthold JE, St. Martin BM, Calve S, Neu CP (2020). Mechanically tunable scaffold that promotes cell migration and chondrogenic differentiation in a dense decellularized articular cartilage matrix both in vitro and in vivo. 2020 Annual Meeting of the Orthopaedic Research Society.

What do you plan to do during the next reporting period to accomplish the goals?

In the next reporting period, we anticipate making significant progress to accomplish our goals. We specifically anticipate continuing activities under Specific Aim 2, including analysis of radiographic data from our *in vivo*, large animal study. We will also continue refining details on microparticle density that promotes graft support, evaluation of tissue integration, identification of cell migration mechanisms *in vitro*. Finally, we will begin preparations for follow-on first-in-human studies, including establishing industry, clinical, and academic partners who may help us advance our technology to the benefit of military personnel and the general public.

IMPACT

What was the impact on the development of the principal disciplines of the project?

Our studies examine the use of new regenerative medicine techniques and therapies to prevent the progression of osteoarthritis. Our work also outlines basic and translational research to identify treatments that mitigate osteoarthritis especially in the knee. We will immediately identify several short-term gains: (1) define fundamental knowledge on microparticle density that promotes graft support, evaluate tissue integration, identify cell migration mechanisms. (2) Complete animal (preclinical) studies that will position us for regulatory discussions with the FDA and funding discussions with potential investors. (3) Determine the extent that cartilage clay protects the cartilage and joint from degeneration, allowing us to transition toward clinical studies in humans.

What was the impact on other disciplines?

Tissue repair is a general problem in medicine, and advanced and effective therapies are generally lacking. We anticipate that the base technology we utilize will be applicable to multiple tissue types for the repair of common problems, including and not limited to musculoskeletal (e.g. ligament, meniscus), neurological (e.g. spinal cord), and immunological (e.g. skin). We envision applying what we learn through activities under this award to address multiple medical needs in future efforts.

What was the impact on technology transfer?

We believe there is significant translational potential for our proposed work, which we expect will move from large animal studies toward first-in-human testing as a natural extension of our results. As a key development in the transition toward commercialization and clinical trials, here we will focus on outcomes in a large animal study. Consequently, we will conduct all animal studies using IACUC approved protocols to ensure compliance with good laboratory practice regulations and animal welfare concerns. After completion of the proposed study, assuming successful outcomes, our plan is to target development toward class III device FDA approval. FDA approval for medical devices goes through the center for devices and radiological health. Past regeneration solutions that have been approved in this center include collagenous matrices, biphasic synthetic osteochondral implants, and hyaluronic acid injections. This is the anticipated regulatory pathway for our device due to the lack of cellularity and minimal processing in the proposed tissue graft. The pathway for approval requires a phased regulatory approach involving three phases. The first phase will be composed of a two-year trial to determine whether the implant is safe for humans and will be a smaller scale study (~20 individuals). If shown to be safe, researchers will pursue funding avenues for stage 2 and 3 clinical trials. The regulatory process is necessary to prove the safety and effectiveness of the technology, and to show that the regenerative benefits outweigh the surgical risks.

The hyaline cartilage repair and regeneration market was valued as a 284.4 million dollar market in 2016, and is projected to grow into a 545.6 million dollar market by 2021. The high growth rate over the next several years is attributed to both the growing obese and geriatric populations, but also the increasing number of active injuries in both athletes and military personnel. The average cost of current cartilage repair procedures ranges from \$4,000 to \$6,000, making these repairs more expensive than a full knee replacement, and highly inaccessible for most of the population. Currently, the major players in the cartilage regeneration market are Zimmer Biomet, Smith and Nephew, Johnson and Johnson, Vericel Corporation, and CONMED. In order to fund the next level of development and commercialization following research proposed for this award, our research team plans to investigate many different funding avenues. We are already partnering with TissueForm, Inc., which is a university spin-out company formed in 2019. TissueForm is a development-stage company with a mission to improve the quality of life in individuals suffering from injury, scarring, aging, and disease, using a proprietary injectable material that serves as a device to provide volumetric support and mechanical stability of volumetric tissue loss. Based on the results of our proposed work, we anticipate that TissueForm will help us to establish a manufacturing pipeline for cartilage clay, in addition to advising and advancing the technology through preclinical and clinical studies that are required for FDA approval. TissueForm is also positioned to establish a distribution network and raise additional (e.g. SBIR, venture capital) funding as we scale manufacturing to reach an increasing base of customers.

What was the impact on society beyond science and technology?

The physical, emotional, and healthcare demands on military service members and veterans are tremendous, especially for those personnel who have sustained combat-related orthopaedic injuries. Our proposal aims to develop new treatment options for soft tissue trauma, which we believe will greatly benefit military personnel by providing expanded options for return of function and improved quality of life. Soft tissue trauma to articular cartilage often results in arthritis and degradation of joints, detrimental loss of ability to perform tasks and mobility, and increased pain and associate healthcare costs. Our proposed development of decellularized and particulated tissues will promote joint preservation and restoration as a preferred option to joint loss or replacement, which will also benefit orthopaedic injuries sustained by the public.

CHANGES/PROBLEMS

Changes in approach and reasons for change?

No Changes / Nothing to Report.

Actual or anticipated problems or delays and actions or plans to resolve them?

No Changes / Nothing to Report.

Changes that had a significant impact on expenditures?

Previously, we reported that due to the COVID-19 pandemic, we were delayed in hiring initial personnel to the project. Additionally, due to immigration policies by the federal government, we lost out on two highly skilled postdoctoral researcher applicants (one from United Kingdom, the other from Japan), who did not feel comfortable moving to and working in the United States. As a result, personnel hiring was delayed, and we have shifted our personnel temporarily to support two graduate students. However, we have now successfully hired a postdoc (as of January, 2021), and we continue to support a graduate student. Consequently, we are excited to now be making excellent progress on all aspects of the project.

Significant changes in use or care of human subjects, vertebrate animals, biohazards, and/or selected agents?

No Changes / Nothing to Report.

Significant changes in use or care of human subject?

No Changes / Nothing to Report.

Significant changes in use or care of vertebrate animals?

No Changes / Nothing to Report.

Significant changes in use of biohazards and/or selected agents?

No Changes / Nothing to Report.

PRODUCTS

Journal Publications.

Barthold JE, St. Martin BM, Sridhar SL, Vernerey F, Schneider SE, Wacquez A., Ferguson V, Calve S, Neu CP (2021). Recellularization and Integration of Dense Extracellular Matrix by Percolation of Tissue Microparticles. <https://www.biorxiv.org/content/10.1101/2020.08.10.245589v1>; doi: <https://doi.org/10.1101/2020.08.10.245589>. (*Currently under final review at Advanced Functional Materials*)

Barthold JE, McCreery K, Bellerjeau C, Bryant SJ, Whiting GL, Neu CP (2021). Particulate ECM Bioink Crosslinking and 3D Printing Form Layered and Lubricated Cartilage Tissue Mimics. (*Currently under review at Advanced Healthcare Materials*)

Books or other non-periodical, one-time publications.

No changes / nothing to report.

Other publications, conference papers, and presentations.

Barthold JE, St. Martin BM, Calve S, Neu CP (2020). Mechanically tunable scaffold that promotes cell migration and chondrogenic differentiation in a dense decellularized articular cartilage matrix both in vitro and in vivo. 2020 Annual Meeting of the Orthopaedic Research Society.

Websites or other internet sites.

No Changes / Nothing to Report.

Technologies or techniques.

No Changes / Nothing to Report.

Inventions, patent applications, and/or licenses.

Provisional Patent Application:

Barthold JE and Neu CP. Particulate materials, formulations, and methods for tissue mimics *in vitro* and *in vivo*. 63/125,280. (Date of filing: 12/14/2020).

Other products.

No Changes / Nothing to Report.

PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS

What individuals have worked on the project?

Name:	Corey Neu
Project Role:	PI
Nearest Person Month Worked:	1.0
Contribution to Project:	Overall project direction, assisting with tissue preparations and analysis.
Funding Support:	Institutional funds, NIH

Name:	Brian Johnstone
Project Role:	Consultant
Nearest Person Month Worked:	1.0
Contribution to Project:	Assisting with experimental design, cell studies and analysis.
Funding Support:	Institutional funds

Name:	Jeremiah Easley
Project Role:	CoInvestigator
Nearest Person Month Worked:	1.0
Contribution to Project:	Initial preparation of Animal Care approvals.
Funding Support:	Institutional funds

Name:	Nancy Emery
Project Role:	CoInvestigator
Nearest Person Month Worked:	1.0
Contribution to Project:	Statistical design and analysis.
Funding Support:	Institutional funds

Name:	Jeanne Barthold
Project Role:	Postdoctoral Researcher
Nearest Person Month Worked:	5.0
Contribution to Project:	Completion of Specific Aim 1.
Funding Support:	

Name:	Adrienn Scott
Project Role:	Graduate Research Assistant
Nearest Person Month Worked:	6.0
Contribution to Project:	Completion of Specific Aim 1.
Funding Support:	

Has there been a change in the active other support of the PI or senior/key personnel since the last reporting period?

Nothing to Report.

What other organizations were involved as partners?

We partner with Colorado State University for animal studies, with the following details:

Organization Name: Colorado State University

Location: Ft. Collins, Colorado.

Financial Support: Subcontract for animal studies initiated in February, 2021, and studies are ongoing.

In-kind Support: Col Easley prepared IACUC forms, anticipating animal studies beginning in 2021.

Facilities: Nothing to Report.

Collaboration: Col Easley performed goat implant studies in February 2021. Management of animals over a 12-month duration is currently ongoing.

Personnel Exchanges: Nothing to Report.

Other: Nothing to Report.

SPECIAL REPORTING REQUIREMENTS

Collaborative Awards

Not Applicable. This is a single PI application.

Quad Charts

All Quad Charts are up to date and complete.

APPENDICES

Nothing to Report.